American Society of Clinical OncologyDuration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

The International Duration of Adjuvant Chemotherapy (IDEA) collaboration investigated whether 3-month adjuvant chemotherapy treatment can be given for colon cancer without compromising efficacy, as six-month adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin doublet is an option for high-risk stage II colon cancer. Here are the results.

American Society of HematologyASH/ISTH/NHF/WFH 2021Guidelines on the Management of von Willebrand Disease

These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of VWD, a common inherited bleeding disorder.

Millennium Medical PublishingA Closer Look at Tazemetostat

In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik, Epizyme), an oral EZH2 inhibitor for the treatment of adult patients with relapsed/refractory follicular lymphoma. Clinical Advances in Hematology & Oncology takes a closer look at this new treatment through a conversation with Dr. Connie Lee Batlevi from MSKCC.

Millennium Medical PublishingTransfusion Replacement Strategies in Jehovah’s Witnesses and Others Who Decline Blood Products

This article reviews a variety of options that are available to aid in caring for patients who refuse blood transfusions, ranging from tranexamic acid to erythropoiesis-stimulating agents. With the use of these treatments, patients who decline blood transfusion can be safely managed in situations ranging from elective surgery to stem cell transplant to pregnancy.

Millennium Medical PublishingHighlights in Metastatic Breast Cancer From the European Society for Medical Oncology Virtual Congress 2020

This review and commentary from the ESMO Virtual Congress 2020 features a look at the following trials: ASCENT (sacituzumab govitecan-hziy), IMpassion130 (atezolizumab + nab-paclitaxel), IMpassion131 (first-line paclitaxel +/– atezolizumab), IPATunity130 (ipatasertib + paclitaxel), SEASTAR (rucaparib + sacituzumab govitecan), FLIPPER (fulvestrant/palbociclib), SOLAR-1 (alpelisib + fulvestrant), and FURVA (vandetanib + fulvestrant).

Millennium Medical PublishingCurrent Antibody-Based Therapies for the Treatment of Multiple Myeloma

Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in MM, discussing  the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.

American Medical AssociationEffect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19

We’ve been hearing about hydroxychloroquine seemingly since the pandemic started, and there is no question that doctors need to determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19. Does this Original Investigation from JAMA finally provide some clarity to the drug’s use among patients hospitalized with the virus?

Healthgrades3 Tips for Overcoming Perfectionism in Doctors

Is perfectionism a net positive? What drives you forward so you can meet your goals and standards? Is it sustainable? It’s perfectly understandable that you strive to deliver the highest quality care for your patients; however, it’s impossible to reach unachievable standards. Fortunately, there are steps you can take to find the balance between accepting […]